Deutsche Bank maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $460. Shares declined after Biogen ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Hot Comments

Baird Downgrades Biogen (BIIB) to Neutral; Diminished Growth ProspectsJuly 27, 2015 6:35 AM Biogen (BIIB) Trading at 'Pharma-Like' Multiple, Cowen SaysJuly 24, 2015 1:04 PM Biogen (BIIB) Worth a 'Hard Look' when Smoke Clears, Stifel SaysJuly 24, 2015 12:19 PM BMO Capital Downgrades Biogen (BIIB) to Market PerformJuly 24, 2015 11:42 AM Biogen (BIIB) Tops Q2 EPS by 12c; Cuts FY15 Revenue Growth, EPS OutlookJuly 24, 2015 6:50 AM Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 BillionJuly 24, 2015 6:50 AM